Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.73 |
| ▸ | ACHE | P22303 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3181878 | 0.83 | ALDH1A1 (0.63) | HRH3ACHELMNAALDH1A1SIGMAR1 | |
| SCHEMBL4267786 | 0.83 | ALDH1A1 (0.63) | HRH3LMNAALDH1A1SIGMAR1CXCR3 | |
| SCHEMBL156202 | 0.83 | HRH3 (0.76) | HRH3ACHEALDH1A1SIGMAR1CXCR3 | |
| SCHEMBL8252094 | 0.83 | HRH3 (0.76) | HRH3ACHELMNAALDH1A1HTR7 | |
| SCHEMBL8275450 | 0.83 | HRH3 (0.76) | HRH3ACHELMNAALDH1A1 | |
| SCHEMBL24105582 | 0.82 | HRH3 (0.69) | HRH3ACHELMNAALDH1A1SIGMAR1 | |
| SCHEMBL17465246 | 0.82 | HRH3 (0.69) | HRH3ACHELMNAALDH1A1HTR7 | |
| SCHEMBL3156587 | 0.82 | LMNA (0.59) | HRH3ACHELMNAALDH1A1SIGMAR1 | |
| SCHEMBL17450448 | 0.82 | LMNA (0.59) | HRH3ACHELMNAALDH1A1SIGMAR1 | |
| SCHEMBL10690328 | 0.82 | LMNA (0.80) | HRH3LMNAALDH1A1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579356-B2 | Thia-tetraazaacenaphthylene kinase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-25 | — | — | US | claimed |
| US-7427625-B2 | Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-09-23 | — | — | US | claimed |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-11-15 | — | — | US | claimed |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-09-27 | — | — | US | claimed |
| CN-114621140-B | Aryldifluoroacetamide compound, preparation method and application thereof | 中国科学院上海药物研究所 | 2023-08-11 | — | — | CN | disclosed |
| CN-114621140-A | Aryl difluoro acetamide compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2022-06-14 | — | — | CN | disclosed |
| CN-108715589-B | Coumarin derivative used as caspase-3 activator and application thereof | 华侨大学 | 2021-04-20 | — | — | CN | disclosed |
| EP-2748166-B1 | PYRIMIDO-PYRIDAZINONE COMPOUNDS AND USE THEREOF | ASANA BIOSCIENCES LLC (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2166860-B1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | INTRA CELLULAR THERAPIES INC (US) | 2016-09-21 | — | — | EP | disclosed |
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | LI PENG (US) | 2016-03-17 | — | — | US | disclosed |
| US-9062023-B2 | Heterocycle compounds and uses thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| EP-1100779-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Boehringer Ingelheim Pharma KG (DE) | 2001-05-23 | — | — | EP | disclosed |
| WO-2001027081-A1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-04-19 | — | — | WO | disclosed |
| EP-1071665-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | Boehringer Ingelheim Pharma KG (DE) | 2001-01-31 | — | — | EP | disclosed |
| US-6169106-B1 | ANTITUMOUR AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-01-02 | — | — | US | disclosed |
| WO-1999062882-A1 | SUBSTITUTED INDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999052869-A1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 1999-10-21 | — | — | WO | disclosed |
| EP-0726893-A1 | NOVEL 4-PIPERIDINYL SUBSTITUTED LACTAMES AS NEUROKININ 2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| US-5534525-A | Lactam derivatives | ZENECA LIMITED (GB) | 1996-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075683-A1 | NOVEL HETEROCYCLE COMPOUNDS AND USES THEREOF | APP, BACE1, PYGB | HRH3 1574/4885ACHE 91/4885LMNA 2952/4885 |
| US-20070225309-A1 | SUBSTITUTED THIATRIAZAACENAPHTHYLENE-6-CARBONITRILE KINASE INHIBITORS | MAP3K11, MAP3K6, MAP4K2 | HRH3 2500/4885ACHE 3897/4885LMNA 2852/4885 |
| US-20070265264-A1 | 5-(3-chloro-4-fluoro-phenyl)-4-oxo-4,5-dihydro-3H-1-thia-3,5,6,8-tetraaza-acenaphthylene-2-carboxylic acid (3,4-dimethoxy-phenyl)-amide | ADK, MAP3K9, MAP4K5 | HRH3 1681/4885ACHE 1320/4885LMNA 3244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.